Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $125 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.4%

Neg 0% Neu 87.4% Pos 0%

Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $125 price target.

Comments

No comments yet. Be the first!